Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.36 |
| ▸ | HTR2B | P41595 | 4/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 2/20 | 0.31 |
| ▸ | DRD5 | P21918 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1171846 | 0.78 | HTR2C (0.40) | HTR2CHTR2BKDM1ASLC6A2HTR2A | |
| SCHEMBL6542656 | 0.75 | HTR2C (0.32) | HTR2CHTR2BKDM1ASLC6A2HTR2A | |
| SCHEMBL1125507 | 0.74 | HTR2C (0.33) | HTR2CHTR2BKDM1ASLC6A2HTR2A | |
| SCHEMBL19780715 | 0.71 | HTR2C (0.45) | HTR2CHTR2BKDM1ASLC6A2HTR2A | |
| SCHEMBL7916402 | 0.70 | HTR2A (0.44) | HTR2CHTR2BSLC6A2HTR2ASLC6A4 | |
| SCHEMBL1914332 | 0.68 | HTR2C (0.36) | HTR2CHTR2BKDM1ASLC6A2HTR2A | |
| SCHEMBL11632118 | 0.68 | HTR2C (0.41) | HTR2CHTR2BKDM1ASLC6A2HTR2A | |
| SCHEMBL1172182 | 0.66 | MEN1 (0.41) | HDAC4NPC1RAB9AMEN1KMT2A | |
| SCHEMBL5717521 | 0.66 | LMNA (0.46) | KMT2A | |
| SCHEMBL29571908 | 0.66 | HTR2C (0.46) | HTR2CHTR2BKDM1ASLC6A2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205409-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2007-04-17 | — | — | US | disclosed |
| US-20050131019-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131019-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | HTR2C 3740/4885HTR2B 3209/4885KDM1A 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.